Takeda has acquired Nimbus Lakshmi, Inc., from Nimbus Therapeutics.

Under terms of the agreement, and upon approval from the Federal Trade Commission (FTC), Takeda will acquire 100% Ownership of Nimbus Therapeutics’ TYK2 Program Subsidiary.

Takeda will pay Nimbus approximately $ 4 billion upfront, after adjusting items including closing indebtedness and closing account payable of Lakshmi.

Takeda will also make two milestone payments to Nimbus of $1 billion each upon achieving annual net sales of $ 4 billion and $5 billion of products developed from the TAK-279 program.

“With our plan to acquire announced in December, we are excited to have promptly added TAK-279, a highly selective oral TYK2 inhibitor with truly transformative potential for patients in multiple diseases, to our late-stage pipeline,” said Ramona Sequeira, president, global portfolio division, at Takeda. “This program closely aligns with our strategy and expertise in immune-mediated diseases, and we look forward to sharing more details of our development plans soon.”

With Phase 3 study in psoriasis expected to start in 2023, TAK-279 has the potential to demonstrate best-in-class efficacy, safety and convenience in psoriasis as well as multiple other immune-mediated diseases, including inflammatory bowel disease, psoriatic arthritis and systemic lupus erythematosus.

The acquisition strengthens Takeda’s growing late-stage pipeline and potentially expands its portfolio and patient impact across multiple indications, reinforcing Takeda’s ability to maintain strong growth globally in the mid- to long-term.